A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain

Abstract Introduction There is no approved effective drug for diabetic peripheral neuropathic pain (DPNP) in China. Gabapentinoids including mirogabalin have shown promise, although data in Chinese patients are scarce. Methods This phase 3, multicenter, randomized, double-blind, placebo-controlled t...

Full description

Bibliographic Details
Main Authors: Xiaohui Guo, Yang Yu, Yongbo Zhang, Li Sun, Yufeng Li, Bing Song, Li Hang, Masayuki Baba, Yosuke Wasaki, Kunika Kikumori, Emiko Murayama
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-06-01
Series:Pain and Therapy
Subjects:
China
Diabetes complications
Neuralgia
Mirogabalin
Phase 3
Online Access:https://doi.org/10.1007/s40122-024-00617-2

Internet

https://doi.org/10.1007/s40122-024-00617-2

Similar Items